メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
大矢 由子
医学部・呼吸器内科学
h-index
1084
被引用数
19
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2015
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(54)
類似のプロファイル
(6)
フィンガープリント
Yuko Oyaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Pneumonia
41%
Lung Cancer
33%
Epidermal Growth Factor Receptor
29%
Pembrolizumab
22%
Non-Small Cell Lung Cancer
21%
Retrospective Cohort Study
20%
Overall Survival
20%
Durvalumab
20%
Chemoradiotherapy
18%
Disease Free Survival
17%
Progression Free Survival
15%
Lobectomy
15%
Immune Checkpoint Inhibitor
15%
Osimertinib
14%
Programmed Death 1 Ligand 1
13%
Intensity Modulated Radiation Therapy
13%
Lung Adenocarcinoma
13%
Adverse Event
13%
Surgery
12%
Hazard Ratio
11%
Retrospective Study
11%
Immunotherapy
10%
Neoplasm
9%
Segmentectomy
8%
Oncogene
8%
Disease
8%
Positron Emission Tomography-Computed Tomography
8%
Gene Mutation
8%
Cohort Analysis
7%
Diagnosis
7%
Clinical Stage
7%
Immune-Related Adverse Events
7%
Programmed Cell Death
7%
Long Term Survival
6%
Carcinoma
6%
Xenon
6%
Lung Function
6%
Lymph Node
6%
Bronchopleural Fistula
6%
Radiofrequency Ablation
6%
EGFR Inhibitors
6%
Lymph Node Metastasis
6%
Chest Tube
6%
Computer Assisted Tomography
6%
Malignant Pleural Effusion
6%
Mediastinal Germ Cell Tumor
6%
Lung Metastasis
6%
Indocyanine Green
6%
Gut Microbiome
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
95%
Epidermal Growth Factor Receptor
68%
Lung Cancer
56%
Osimertinib
29%
Chemotherapy
29%
Immune Checkpoint Inhibitor
29%
Cohort Study
28%
Pneumonia
28%
Anaplastic Lymphoma Kinase
26%
Progression Free Survival
26%
Crizotinib
20%
Adverse Event
20%
Overall Survival
17%
Pembrolizumab
17%
Programmed Cell Death
14%
Programmed Death 1 Ligand 1
14%
Protein Tyrosine Kinase Inhibitor
12%
Monotherapy
10%
Malignant Neoplasm
9%
Combination Therapy
8%
Disease
8%
Nivolumab
8%
Alectinib
7%
Biological Marker
7%
Chemoradiation Therapy
6%
Xenon
6%
Malignant Pleura Effusion
6%
Quantum Dot
6%
Small Cell Lung Cancer
6%
Adenocarcinoma
6%
Bronchopleural Fistula
6%
Ceritinib
6%
Indocyanine Green
6%
Postoperative Complication
6%
Immunotherapy
6%
Fenbendazole
6%
Protein Mcl 1
6%
Retrospective Study
6%
Brain Metastasis
5%
Interstitial Lung Disease
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
49%
Osimertinib
23%
EGFR mutation
21%
Epidermal Growth Factor Receptor
20%
Overall Survival
14%
Clinical Outcomes
14%
Pneumonitis
14%
Elderly Patients
13%
Non-elderly
13%
Confidence Interval
13%
Immune Checkpoint Inhibitors
12%
Hazard Ratio
10%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
9%
Chemotherapy
8%
T790M mutation
8%
Immune Checkpoint Inhibitor Therapy
8%
Risk Factors
8%
Lung Cancer
8%
Non-small Cell Lung Cancer Patients
7%
Elderly People
7%
ALK Rearrangement
6%
Total Lesion Glycolysis
6%
Spectrophotometry
6%
Fluorimetry
6%
Genomic Test
6%
Nanodrop
6%
Qubit
6%
Immune-related Adverse Events
6%
High Risk Histology
6%
Concurrent Chemotherapy
6%
Sublobar Resection
6%
Adverse Events
6%
IrAE
6%
Guideline Methodology
6%
Intensity-modulated Radiation Therapy
6%
Propensity Score Analysis
6%
Crimson
6%
Real-world Survey
6%
PD-1 Inhibitor
6%
ROS1 Rearrangement
6%
Small Cell Lung Cancer Transformation
6%
Stage IV NSCLC
6%
Corticosteroids
6%
Multicenter Retrospective Study
6%
Ceritinib
6%
EGFR T790M
6%
Retrospective Analysis
6%
Anaplastic Lymphoma Kinase Fusion
6%
Fusion Variants
6%
Stage III Non-small Cell Lung Cancer
6%